BenevolentAI is a clinical-stage AI-enabled drug discovery company that uses combined capabilities of artificial intelligence, scientific expertise, and wet-lab facilities to deliver novel drug candidates with higher probability of clinical success than those developed using traditional methods. The company's AI Platform powers an in-house pipeline spanning from target discovery to clinical studies across multiple therapeutic indications.
BenevolentAI is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Employees
150–250
Total Funding
$730M
4 rounds
Latest Valuation
$1.63B
April 25, 2022
Total raised $730M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
SPAC merger / IPO
Date
April 25, 2022
Amount
$425M
Valuation
$1.63B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| April 25, 2022 | SPAC merger / IPO | $425M | $1.63B | Odyssey Acquisition |
| September 2019 | Strategic (Temasek) | $90M | $1B | Temasek |
| April 2018 | Growth round | $115M | $2B | Woodford Investment Management |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Growth round
$2B
Apr 2018
BenevolentAI today
$1.6B
Apr 2022 · latest mark
BenevolentAI multiple
0.8x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Kenneth Mulvany
Executive Chairman & Founder
Michael Brennan
Chief Strategy and Financial Officer & Co-Founder
Ivan Griffin
Chief Operating Officer & Co-Founder
Joanna Shields
Chief Executive Officer (as of April 2022)
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Atomwise
AI drug discovery platform using convolutional neural networks (CNNs) and deep learning neural networks (AtomNet) to predict molecular interactions and binding affinity
Insilico Medicine
AI-powered drug discovery and development platform focused on generative models and predictive analytics for therapeutic discovery
Exscientia
AI drug discovery platform enabling faster identification and design of drug candidates across multiple therapeutic areas
Recursion Pharmaceuticals
AI-driven drug discovery company using machine learning and phenotypic screening to identify novel therapeutics
DeepMind (Google)
AI research lab owned by Google using AlphaFold protein structure prediction to enable faster drug candidate identification
Schrodinger
AI-powered computational chemistry and drug discovery platform for predicting molecular properties and optimizing drug candidates
BenevolentAI completed a SPAC merger with Odyssey Acquisition S.A. on April 22, 2022, and began trading on Euronext Amsterdam under ticker BAI on April 25, 2022, with gross proceeds of EUR 225 million (approximately $1.7B post-money valuation). The company delisted from Euronext Amsterdam on March 13, 2025, following a merger with Osaka Holdings S.à r.l., returning to private company status.
BenevolentAI shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
BenevolentAI had a valuation of approximately $1.63B at the time of its public offering. Current market capitalization fluctuates with the share price.
BenevolentAI raised $730M across 4 disclosed funding rounds prior to its public listing.
BenevolentAI was co-founded by Kenneth Mulvany, Michael Brennan, and Ivan Griffin in 2013.
BenevolentAI is headquartered in London, UK.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.